In April 2021, the FDA lifted the in-person dispensing requirement for mifepristone due to the Covid-19 pandemic. In a surprising turn, this requirement was permanently lifted in 2023. Yet, recent court rulings have thrown this progress into disarray.

The Fifth Circuit Court of Appeals issued a stay that blocks the use of mifepristone, directly impacting its availability. U.S. District Judge Matthew Kacsmaryk suspended the FDA’s approval of mifepristone, leading to confusion and upheaval in medical practices.

As a response, organizations like Planned Parenthood are adapting. Nicole Clegg, President and CEO of Planned Parenthood of Northern New England, remarked on their strategy: “We closely monitored this court case, and we identified a way to keep telehealth medication abortion access intact for our patients.” They plan to switch to misoprostol-only for telehealth patients.

This legal turmoil stems from a lawsuit filed by individual doctors and medical groups opposed to abortion. The FDA and several leading medical groups argue that mifepristone is safe and effective. However, the court’s decisions suggest otherwise.

Danco Laboratories and GenBioPro manufacture mifepristone, which is typically used alongside misoprostol for medication abortions. The combination has been standard practice since mifepristone’s approval back in 2000.

Now, with the legal landscape shifting rapidly—regulatory chaos looms. GenBioPro stated that “the order has unleashed regulatory chaos,” highlighting the immediate impact on healthcare providers.

The next significant legal ruling is expected in early 2024 concerning the case FDA v. Alliance for Hippocratic Medicine. Until then, uncertainty reigns over how these legal battles will shape abortion access moving forward.

The post Mifepristone: Legal Battles Reshape Abortion Access appeared first on News Canada.

The regulatory environment for tirzepatide has changed substantially since the FDA confirmed that the tirzepatide injection drug shortage has been resolved. This development is significant for MEDVi, a telehealth platform that provides access to GLP-1 weight loss medications, which has been navigating a challenging market landscape.

MEDVi has positioned itself as a competitive player in the weight loss medication space, offering compounded GLP-1 injections starting at $179 for the first month, with refills priced at $299 per month. In contrast, the branded Ozempic injection is listed at a staggering $1,999 per month, highlighting the cost-effective alternatives MEDVi provides.

In 2025, MEDVi reported an impressive $401 million in sales, and projections indicate that this figure could soar to $1.8 billion in 2026. This rapid growth is attributed to the strategic use of AI tools and partnerships, as noted by CEO Matthew Gallagher, who remarked, “Growth was insane.”

MEDVi’s business model includes a conditional refund policy for weight loss after five months, which requires a minimum commitment before a refund can be requested. This policy reflects the company’s confidence in the efficacy of its offerings, although it also underscores the time it takes for patients to acclimate to GLP-1 medications, as noted by healthcare professionals.

As MEDVi continues to expand its customer base—from just 300 customers in its first month to 1,300 in the second—its operational strategies and pricing models will be closely watched by industry observers. The company operates from its headquarters in Newark, DE, and is structured as a Delaware corporation.

With the resolution of the tirzepatide shortage, MEDVi is poised to capture a larger share of the market, appealing to consumers seeking effective weight loss solutions through telehealth. The evaluating clinician retains the decision to prescribe, ensuring that patient care remains a priority amidst the company’s growth.

Looking ahead, industry analysts anticipate that MEDVi’s innovative approach and competitive pricing will further solidify its position in the telehealth sector, particularly as demand for weight loss medications continues to rise. The company’s ability to adapt to regulatory changes and market dynamics will be crucial in maintaining its momentum.

The post MEDVi’s Surge Amid Tirzepatide Market Changes appeared first on News Canada.